Under construction – not a live service
Sign in
Taking people in DenmarkPhase 2

Monitoring and treatment after stem cell transplant for myelodysplastic syndrome

Tests treatment guided by residual disease markers in adults with myelodysplastic syndrome after transplant.

Key facts

Who runs it
Karolinska University Hospital
Where
Aarhus N and Copenhagen Oe, DenmarkSee the 2 sitesAlso in 3 other countries, 9 sites
Registry title
NMDSG-14B2
Status
Recruiting
Phase
Phase 2
People taking part
200 people, planned
Started
21 Sept 2021
Planned end
1 Oct 2025
Type of study
Interventional
Record updated
27 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with myelodysplastic syndrome (MDS) who can have a stem cell transplant. It tests treatment after transplant, guided by traces of leftover disease.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Myelodysplastic syndrome (MDS), mixed myelodysplastic/myeloproliferative syndrome, or acute myeloid leukemia (AML) with myelodysplasia related dysplasia and 20-29% marrow blasts.
Biomarker or test result
A traceable genetic change must have been found, either in the screening sequencing panel or in the one done at diagnosis.

Main reasons for not taking part

  • No traceable genetic change found
  • Uncontrolled high blood pressure
  • Uncontrolled heart, liver, kidney or other medical or psychiatric disorders
  • Mental inability, reluctance or language difficulties that make it hard to understand taking part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Signed informed consent
  • Age ≥ 18 years
  • Subjects eligible for stem cell transplantation
  • Subjects having the disease myelodysplastic syndrome (MDS), mixed myelodysplastic/myeloproliferative syndrome or acute myeloid leukemia (AML) with myelodysplasia related dysplasia and 20-29% marrow blasts
  • All female subjects of childbearing potential have to have negative pregnancy test within 2 weeks prior to inclusion to the study

Who cannot take part

  • Uncontrolled hypertension, heart, liver, kidney related or other uncontrolled medical or psychiatric disorders
  • No traceable genetic aberration identified either in screening next generation sequencing panel or next generation sequencing panel performed at diagnosis
  • Mental inability, reluctance or language difficulties that results in difficulty understanding the meaning of study participation

Where in Denmark

Also in 3 other countries, 9 sites

  • Aarhus University HospitalAarhus N, DenmarkTaking people
  • RigshospitaletCopenhagen Oe, DenmarkTaking people

About the trial

What the trial wants to find out

To prevent clinical events (relapse or non-relapse death) in minimal residual disease (MRD) positive subjects

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
A phase II multicenter single-armed study using subject-specific minimal residual minimal disease markers to adopt treatment after allogeneic stem cell transplantation for subjects with myleodysplastic syndrome - MDS
Plain-language title
Monitoring and treatment after stem cell transplant for myelodysplastic syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
27 May 2026